Steil G M, Panteleon A E, Rebrin K
Medtronic MiniMed Department, Sensor R&D, 18000 Devonshire St., Northridge, CA 91325-1219, USA.
Adv Drug Deliv Rev. 2004 Feb 10;56(2):125-44. doi: 10.1016/j.addr.2003.08.011.
The development of an artificial pancreas for the treatment of insulin-dependent diabetes is a highly desired endeavor for patients, physicians, scientists, and engineers. Historical algorithms and recent progress in research and technology are reviewed in the present article, together with aspects of beta-cell physiology that lead to normal glucose tolerance. Algorithms are evaluated for their ability to deliver insulin as to recreate, as closely as possible, glucose and insulin profiles observed in healthy individuals. Emphasis is placed upon how the algorithms compare to the beta-cell's secretory response, specifically first-phase and second-phase insulin secretion. Experimental closed-loop data employing intravenous and subcutaneous glucose sensors and implanted and external insulin pumps (Medtronic MiniMed, Northridge CA) are presented.
开发用于治疗胰岛素依赖型糖尿病的人工胰腺,是患者、医生、科学家和工程师们热切期望的一项工作。本文回顾了历史算法以及研究与技术方面的最新进展,同时还介绍了能实现正常糖耐量的β细胞生理学方面的内容。对算法进行评估,看其输送胰岛素的能力,能否尽可能重现健康个体中观察到的血糖和胰岛素情况。重点在于这些算法与β细胞分泌反应(特别是第一阶段和第二阶段胰岛素分泌)的比较情况。本文还展示了使用静脉和皮下葡萄糖传感器以及植入式和外置胰岛素泵(美敦力MiniMed,加利福尼亚州诺斯里奇)的实验闭环数据。